The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Rilpivirine
Rilpivirine · RILPIVIRINE HYDROCHLORIDE 25 mg/1 · Tablet, Film Coated · Oral · Laurus Labs Limited
NDC 42385-0999-30 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- ANDA219788
- TE code
- AB
- Approval date
- Jul 10, 2026
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Rilpivirine (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Somerset Therapeutics, LLC | RILPIVIRINE HYDROCHLORIDE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Laurus Labs Limited | RILPIVIRINE HYDROCHLORIDE 25 mg/1 | Jul 18, 2026 | Aug 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Rilpivirine — NDC 42385-0999-30," retrieved September 3, 2026, https://drugdashboards.com/drug/42385099930.
Free to cite with attribution — see how the data is put together.